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Abstract
Background: Spontaneous reporting systems for adverse drug reactions (ADRs) are handicapped
by under-reporting and limited detail on individual cases. We report an investigation from a local
surveillance for serious adverse drug reactions associated with disease modifying anti-rheumatic
drugs that was triggered by the occurrence of liver failure in two of our patients.
Methods: Serious ADR reports have been solicited from local clinicians by regular postcards over
the past seven years. Patients', who had hepatotoxicity on sulfasalazine and met a definition of a
serious ADR, were identified. Two clinicians reviewed structured case reports and assessed
causality by consensus and by using a causality assessment instrument. The likely frequency of
hepatotoxicity with sulfasalazine was estimated by making a series of conservative assumptions.
Results:  Ten cases were identified: eight occurred during surveillance. Eight patients were
hospitalised, two in hepatic failure – one died after a liver transplant. All but one event occurred
within 6 weeks of treatment. Seven patients had a skin rash, three eosinophilia and one interstitial
nephritis. Five patients were of Black British of African or Caribbean descent. Liver enzymes
showed a hepatocellular pattern in four cases and a mixed pattern in six. Drug-related
hepatotoxicity was judged probable or highly probable in 8 patients. The likely frequency of serious
hepatotoxicity with sulfasalazine was estimated at 0.4% of treated patients.
Conclusion: Serious hepatotoxicity associated with sulfasalazine appears to be under-appreciated
and intensive monitoring and vigilance in the first 6 weeks of treatment is especially important.
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Background
Spontaneous reporting systems for adverse drug reactions
(ADRs), such as the yellow card system run by the Medi-
cines and Healthcare products Regulatory Agency
(MHRA) in the UK and the US Medwatch system, are
handicapped by under-reporting and provide limited
detail on individual cases. In an effort to learn more about
ADRs associated with disease modifying anti-rheumatic
drugs (DMARDs) we set up a local reporting system seven
years ago[1] and reported preliminary findings in 2002
[2].
Case reports of serious hepatotoxicity associated with sul-
fasalazine are common yet only 161 ADRs attributed to
the liver and biliary system have been reported to the
Medicines and Healthcare products Regulatory Agency
(MHRA) including nine fatalities [3]. In the US six
patients developed drug related liver failure associated
with sulfonamides in 2005 [4]. Drug 'hypersensitivity'
reactions which include a morbilliform rash and hepatitis
have, most recently, been called the DRESS (Drug Rash
with Eosinophilia and Systemic Symptoms) syndrome
[5,6] a term that places emphasis on eosinophilia. How-
ever serious toxicity without eosinophilia but including
hepatitis is well recognised and older terms for this reac-
tion, which occurs with other drugs such as car-
bamazepine and dapsone, have been called the 'three
week syndrome' or the 'sulphone syndrome' [7,8].
Case reports are an important source of data which can
guide management of new cases and trigger pharmaco-
epidemiological investigations that may determine the
probability of drug related toxicity. Drug related hepato-
toxicity is an important cause of morbidity and mortality
and indeed is the most common reason for withdrawing
new drugs [9]. In this investigation, which was triggered
by the occurrence of liver failure in two of our patients tak-
ing sulfasalazine, we describe a series of patients who
developed serious hepatotoxicity whilst taking sulfasala-
zine.
Methods
We have solicited reports of serious ADRs related to
DMARDs from health care professionals treating patients
with rheumatic disease in our institution by sending a
postal or email postcard every 2 to 4 weeks over a period
of 7 years. Details were requested for patients receiving
DMARDs for RA or seronegative arthritidies. At inception
we canvassed reports from colleagues in other local hospi-
tals [2] but currently postcards and emails are targeted pri-
marily at staff in our unit. We began in October 1999
when the first event was reported. A widely used defini-
tion of serious ADRs [10] was given in our early postcards
but latterly any event regarded by a clinician as serious has
been logged on our database. Clinicians are able to report
serious events spontaneously or when prompted. This
investigation was instigated when we became aware that
two of our patients had developed liver failure whilst tak-
ing sulfasalazine.
Patients taking sulfasalazine and who developed a serious
ADR which included hepatotoxicity were identified from
our database. Identified cases were assessed for whether
they met the definition of a severe or a life-threatening
event according to the common toxicity criteria agreed by
OMERACT (Outcome Measures in Rheumatology Clinical
Trials) [11]. Thus, patients had to have major functional
impairment of any duration associated with a rise in
transaminases of at least 3 times the upper limit of nor-
mal, or a similar rise in alkaline phosphatase, or both.
Concomitant jaundice was not necessary. One senior cli-
nician made these judgments (PJ). For those meeting
these criteria a detailed case report was prepared. The pat-
tern of hepatatoxicity according to serum liver enzyme
changes was classified as hepatocellular (transaminases
above 2× normal alone or ratio of transaminases to alka-
line phosphatase ≥ 5), cholestatic (increase in alkaline
phosphatase above 2× normal or when ratio of enzymes
is ≤ 2) or mixed according to agreed international criteria
[12]. Case reports were reviewed by two senior clinicians
who agreed, by consensus, whether the likelihood of
drug-related hepatotoxicity was: highly probable; proba-
ble; possible; unlikely; or excluded. Two clinicians also
used a detailed clinical index used for 'Causality Assess-
ment of a Drug in a Case of Acute Liver Injury' [12,13].
This index was used in an effort to improve the probabil-
ity that true drug related ADRs were identified [14]. The
index includes domains for temporal relationship
between drug use and adverse event, course of illness, con-
sideration of other risk factors and search for non-drug
causes, concomitant drug use and effects on re-challenge,
if done.
We estimated the frequency of serious hepatotoxicity
associated with sulfasalazine by making a series of con-
servative estimates and by using published data on the
incidence of rheumatic diseases and the likely use of sul-
fasalazine.
Results
Case Series
In November 2006, when our analysis was done, our
database had 203 reports of serious ADRs: 38 relating to
sulfasalazine and 30 of these from one institution (Uni-
versity Hospital Birmingham). Nine other reported events
were removed from the database because there was no
suggestion of drug related toxicity. One patient who had
developed upper gastrointestinal symptoms on sulfasala-
zine with abnormalities of liver function tests necessitat-
ing drug cessation was excluded as alanine transferase orBMC Musculoskeletal Disorders 2008, 9:48 http://www.biomedcentral.com/1471-2474/9/48
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alkaline phosphatase levels were not sufficiently raised
(levels were below twice the upper limit of normal). Ten
patients met our inclusion criteria for a serious adverse
event: 8 reported during the surveillance period, 1 from
some years previously and 1 reported by colleagues from
a neighbouring hospital. By contrast, there were 63
reports of ADRs associated with methotrexate – 2 of these
indicated liver disease, in one instance associated with
alcohol excess.
The characteristics of the 10 patients with hepatitis whilst
on sulfasalazine and their outcomes are shown in the
Tables 1 &2. Five patients had a clinical diagnosis of RA,
one possible RA, and the remaining 4 had sero-negative
arthritidies. Six of the 10 patients had disease duration of
less than a year. All patients had normal liver function
tests before starting sulfasalazine including alkaline phos-
phatase, albumin, bilirubin and transaminases. None of
the patients started any other new medications at the time
of starting sulfasalazine. However all patients were using
other drugs, in some cases potentially hepatotoxic medi-
cation such as diclofenac, when starting sulfasalazine (see
Table 1). Eight of the 10 patients were hospitalised: three
were admitted to the regional liver unit with jaundiced
and two of these were in hepatic failure. Both the latter
patients had a liver transplant but one died a few weeks
after transplantion. Other causes of hepatitis were consid-
ered and investigated but exhaustive investigations were
not done in all cases.
All but three patients had liver and gallbladder ultrasound
scans and/or an abdominal CT. Both patients with liver
failure showed normal hepatic architecture on imaging.
The third patient admitted to the liver unit showed a fatty
liver. Gallstones were not seen. Serological tests for hepa-
titis B and C were done acutely in five of the ten patients
and in a sixth a year later: tests were negative in all cases,
details are shown in Table 2. Five patients had tests for
cytomegalovirus, none tested positive for IgM. Patient 3,
who had interstitial nephritis, was tested for human her-
pesvirus 6 and was negative.
Liver tissue from patient 5, who died, showed expanded
portal tracts with a dense inflammatory infiltrate of
mononuclear cells, mixed lymphocytes, plasma cells and
some blast forms. Bile ducts showed similar inflamma-
tion and the liver parenchyma showed spotty infiltration
with inflammatory cells and bridging necrosis. Hepatic
veins showed subendothelial inflammation. An excess of
eosinophils was not reported. Liver histology from patient
6, who also developed liver failure, showed massive hepa-
tocyte necrosis with a mixed inflammatory cell infiltrate
and little surviving parenchyma. Moderate numbers of
eosinophils were noted. Variable portal tract inflamma-
tion was also seen. Other causes of liver failure such as
Wilson's disease and alpha-1-antitrypsin deficiency were
excluded in these two patients.
All but one event occurred within 6 weeks of starting treat-
ment. Most patients felt generally unwell, 7 had a skin
rash and one patient, with interstitial nephritis on biopsy,
developed renal impairment (maximum creatinine 250
μmol/litre). Five of the 10 patients were Black British of
African or Caribbean descent: racial type was assigned
from personal knowledge of patients, hospital demo-
graphic data and by applying categories given in the 2001
Table 1: Patient characteristics
Patient No./Age/
Sex/Race*
Diagnosis* & Duration Time on drug† Concomitant medication‡ Alcohol units/wk
1/46/M/WB PsA 20 years 2 days (On re-challenge) Piroxicam, temazepam, paracetamol and 
dextropropoxyphene.
8 units
2/35/F/WB RA 3 months 14 days Diclofenac, paracetamol and 
dextropropoxyphene.
None
3/35/M/BB ReA ~3 months 31 days Diclofenac, flucloxacillin, paracetamol with 
dihydrocodeine
8 units
4/50/M/WB PsA 28 months >270 days Felodipine, lansoprazole. >30 units
5/33/F/BB RA 23 months ~14 days Celecoxib None
6/30/F/WB RA <3 months 5 days Diclofenac. Methylprednisolone 120 mg intra-
muscularly before starting sufasalazine.
None
7/64/F/BB RA 10 years ~12 days Chlorpheniramine, lisinopril, aspirin, cetirizine. 
Inhaled steroids & β-agonists
None
8/37/F/BB RA 7 months ~42 days Rofecoxib, prednisolone, paracetamol with 
dihydrocodeine, aspirin, folic acid.
None
9/45/F/WB ?RA 6 months ~17 days Sertraline None
10/48/F/BB RA 3 months 10 days Lansoprazole, tramadol, stemetil, thyroxine, 
rofecoxib, co-proxamol
None
* WB – White British, BB – Black British of African or Carribean descent. PsA: Psoriatic arthritis. RA: rheumatoid arthritis. ReA: reactive arthritis.
† For episode related to adverse event. ‡ At the time of adverse event.BMC Musculoskeletal Disorders 2008, 9:48 http://www.biomedcentral.com/1471-2474/9/48
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census of England & Wales [15]. Liver enzymes showed a
mixed pattern in 6 cases and a hepatocellular pattern in
four. Likelihood of drug-related hepatotoxicity was
judged highly probable in 7; probable in 1; and possible
in 2 cases by two senior clinicians. Scores obtained by
applying a published index for evaluating causality of
drug related liver toxicity were poorly correlated with the
clinical judgement of clinicians (see Table 2).
Estimating the frequency of sulfasalazine related 
hepatotoxicity
We estimated the incidence of hepatotoxicity by making a
series of assumptions which tend to underestimate the fre-
quency of hepatotoxicity associated with sulfasalazine.
The incidence of RA may be as high as 54 per 100000
female population and 25 per 100000 males [16]. The
West Midlands, in England, has as many men as women
and the city of Birmingham a population of around
977,000 [17]. One hundred and fifty eight new patients
with RA per annum would be expected in the catchment
area of University Hospital Birmingham (population
served 400,000). We assumed that the other inflamma-
tory arthritides combined contribute a further 42 patients
per annum, bearing in mind that the incidence rate for
psoriatic arthritis is between 3 to 8 per 100000 adults
[18]. Our surveillance covers 7 years so potentially 1400
new patients may have developed an inflammatory arthri-
tis. Assuming that all were referred to hospital, all given
DMARDs, but that sulfasalazine was used in only 50%,
based on a survey of UK practice [19], over 7 years 700
patients may have started sulfasalazine. The number of
patients with prevalent inflammatory arthritis who also
started sulfasalazine during this period cannot be esti-
mated readily. However it is plausible that an equal
Table 2: Clinical Features & Outcomes
Pat. No. Clinical features# including liver enzymes** Probability¶ & causality 
index score§
Outcome
1 Systemically unwell, fever, rash. No eosinophilia. RF & ANA -ve. 
Transaminases >7× & alk. phos. >2× ULN. Bilirubin <2× ULN. 
Hepatocellular pattern. Hepatitis B & C status unknown.
Highly probable 4 Recovered
2 Nausea, dizziness, pruritis, rash, headache. No eosinophilia. RF -ve. ANA 
1:400. Transaminases >2× & alk. phos. >8× ULN. Bilirubin <2× ULN. 
Mixed pattern. Hepatitis B & C status unknown.
Highly probable 2 Recovered
3 Lymphadenopathy, rash, fever, headaches, interstitial nephritis. 
Eosinophilia. RF & ANA -ve. Transaminases >4× & alk. phos. >2× ULN. 
Bilirubin <2× ULN. Mixed pattern. Hepatitis B & C status unknown.
Highly probable 6 Recovered. Given steroids.
4 Jaundice, systemically unwell. No eosinophilia. ANA-ve. RF not done. 
Transaminases >4× & alk. phos. >8× ULN. Bilirubin >10× ULN. Mixed 
pattern. Hepatitis B & C negative.
Possible 4 Recovered
5 Hepatic failure, rash, fever, diarrhoea. Lymphocytosis. No eosinophilia. 
ANA 1:40. RF +ve. Transaminases >50× & alk. phos. >1.5× ULN. Bilirubin 
>10× ULN. Hepatocellular pattern. Hepatitis B, C, & CMV negative.
Highly probable 8 Given steroids. Died after 
liver transplant
6 Hepatic failure preceded by nausea, vomiting, abdominal pain, diarrhoea. 
Eosinophilia. RF & ANA-ve. Transaminases >250× & alk. phos. >2× ULN. 
Bilirubin >6× ULN. Hepatocellular pattern. Hepatitis B, C & CMV 
negative.
Highly probable 9 Recovered after liver 
transplant
7 Abdominal pain, anorexia, nausea, rash, hypotension. Monocytosis. No 
eosinophilia. RF & ANA -ve. Transaminases >4× & alk. phos. >2.5× ULN. 
Bilirubin <2× ULN. Mixed pattern. Hepatitis B, C, & CMV negative.
Probable 7 Recovered
8 Nausea, vomiting, fever, rash, pruritus, sweating. Monocytosis & 
Eosinophilia. RF +ve. ANA 1:1600 post sulfasalazine. No pre-treatment 
value ANA. Transaminases >28× & alk. phos. >2.5× ULN. Bilirubin >2× 
ULN. Hepatocellular pattern. Hepatitis B, C & CMV negative.
Highly probable 7 Given steroids. Recovered
9 Lethargy, rash, dry cough, fever. Monocytosis. No eosinophilia. RF & ANA 
-ve. Transaminases >10× & alk. phos. >2× ULN. Bilirubin <2× ULN. Mixed 
pattern. Hepatitis B, C & CMV negative.
Highly probable 4 Recovered
10 Abdominal pain, nausea, vomiting, dizziness, palpitations, worsening joint 
pain. No eosinophilia. ANA 1:100. RF+ve. Transaminases >4× & alk. phos. 
>5× ULN. Bilirubin <2× ULN. Mixed pattern. Hepatitis B & C status 
unknown.
Possible 2 Given steroids. Recovered
# Eosinophilia refers to any value above normal. Some patients had a rise in eosinophil count above baseline but levels did not rise above the normal 
range. ** ULN = upper limit of normal. Pattern of toxicity classified as hepatocellular or mixed/cholestatic using published criteria [12].
¶Probability was determined by consensus and the clinical judgement of two senior clinicians according to a 5 point scale: highly probable, probable, 
possible, unlikely or excluded. & § Causality index scores were determined according to the methods described by Danan and Benichou (reference 
12). A score of between -9 and +15 is possible on this scale: scores of <0 are considered to exclude drug toxicity; of 1–2 as 'unlikely'; 3–5 as 
'possible'; 6–8 as 'probable' and over 8 'highly probable'. ANA: Anti-nuclear antibody. RF: rheumatoid factor. CMV:BMC Musculoskeletal Disorders 2008, 9:48 http://www.biomedcentral.com/1471-2474/9/48
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number of patients with prevalent disease rather than
newly diagnosed patients also started sulfasalazine i.e.
700 (the prevalence of RA for a population of 400,000 is
estimated at 3200 [20]). Eight patients from the popula-
tion served by University Hospital Birmingham devel-
oped serious hepatotoxicity during surveillance: 6 within
one month of therapy. We estimate, therefore, that 0.4%
(6/1400) of patients treated with sulfasalazine in our pop-
ulation developed serious hepatotoxicity: 4 were of a
Black British background whereas around 12% of our
catchment has this ethnic background [21] indicating that
risk of hepatotoxicity is significantly higher in this ethnic
group.
Discussion
We estimated that the frequency of hepatitis with sul-
fasalazine was approximately 0.4% in our population.
Two of our patients developed liver failure – an estimated
rate of about 1.4 in 1000 people treated. It is possible that
a higher than expected frequency of events occurred by
chance during our surveillance and that the actual rate is
lower: our estimates are in excess of those suggested by
reviews of drug induced hepatotoxicity [22]; rates
reported in observational studies; and data reported to the
Committee for Safety of Medicines in the UK. For exam-
ple, Ransford and Langman reported that 8.6 hepatitis
reactions occurred per million prescriptions in RA
patients compared with 3.1 per million prescriptions for
people with inflammatory bowel disease [23]. Amos and
colleagues, in another observational study, showed that
only 2 of 774 patients stopped sulfasalazine because of
abnormal liver enzymes [24]. However 26% of patients
ceased therapy in their study within 1 year because of tox-
icity and a majority because of nausea, abdominal pain
and vomiting: symptoms that were commonly encoun-
tered in our series with hepatitis and which often led to
uncertainties about diagnosis. Despite reservations about
our estimates, under reporting of serious adverse events,
even for drugs under special surveillance, is well known
and only half of all cases identified by prescription event
monitoring are notified spontaneously [25]. Indeed a
majority of the events related to sulfasalazine reported in
this study (30 of 38) were from one institution indicating
under-reporting from other centres involved at the begin-
ning of our surveillance.
Most ingested sulfasalazine reaches the large bowel
unchanged where it is split by colonic bacteria into sulp-
hapyridine and 5-aminosalicylic acid (mesalazine). The
latter remains in the large bowel but sulphapyridine is
largely absorbed and eliminated in urine, principally after
acetylation. Acetylation is determined by polymorphisms
of the N acetyl transferase type II (NAT2) gene of which
over 30 are known [26]. Between 40 and 70% of Euro-
pean and African populations, and less than a third of Far
Eastern populations, are slow acetylators. Toxicity due to
sulfasalazine including hepatitis appears, in general, to be
more common in slow acetylators [27-29]. Thus an excess
of Black British individuals with an African or Caribbean
background in our series cannot readily be explained by
current data for NAT2 genotype and phenotype and other
explanations need to be considered. We do not know
whether the reported excess of hepatitis and leucopenia
attributed to sulfasalazine in RA patients compared with
that in people with inflammatory bowel disease [23] is
due to disease, patient characteristics, or reporting bias
because of differences in monitoring practices between
rheumatologists and gastroenterologists.
Drug induced hepatotoxicity may occur as a direct result
of a drug or it's metabolites on hepatocytes or via immune
activation. Reactions to sulfasalazine are believed to arise
because of an idiosyncratic delayed-type hypersensitivity
reaction that may affect internal organs variably. Fatalities
may occur in 10% or more cases and are commonly due
to liver involvement [30]. It is suggested that this is due to
eosinophil infiltration of the liver [31]; eosinophilia on
liver biopsy was noted in one of our patients with liver
failure. However it is also reported that there are no spe-
cific histological features associated with drug induced
hepatitis [32]. Treatment of drug related hepatotoxicity is
supportive in most cases [30]. Cessation of suspected
drugs is vital and steroids are commonly used although
there is no clear consensus that they are effective [31].
Four of our patients were given steroids and the patient
with liver failure who survived had received an intra-mus-
cular injection of methylprednisolone just prior to start-
ing sulfasalazine.
Toxicity without typical features of hypersensitivity, such
as a skin rash, is well recognised [33]. Adverse reactions to
sulphonamides are more common in the presence of viral
infections such as human immunodeficiency virus [34]
and perhaps human herpes simplex-6 (HHV6) although
the one patient we tested for HHV6 was negative [35]. Sys-
temic reactions to sulfasalazine and other drugs which
include eosinophilia have been dubbed the DRESS syn-
drome. Associated interstitial nephritis is less common
and likely to be due to mesalazine [23]. In our series eosi-
nophilia was not invariable and we concur with Peyriére
and colleagues that this term is unnecessarily restrictive
[36]. The term 'three week syndrome' is older and accu-
rately describes the timing of serious toxicity: it is worth
noting that both the British Society for Rheumatology
guidelines [37] and the summary of product characteris-
tics for salazopyrin [38] recommend that liver function
tests should be monitored every 4 weeks initially. Thus a
majority of our patients would not have been identified
by national monitoring recommendations. Our practice is
prescribe sulfasalazine at 500 mg per day in week 1 andBMC Musculoskeletal Disorders 2008, 9:48 http://www.biomedcentral.com/1471-2474/9/48
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increase weekly by 500 mg up to 2 g per day at week 4. We
monitor blood every 2 weeks for the first 12 weeks of ther-
apy [39]. This policy was in place at the time these events
occurred and no deviations from our policy were identi-
fied. The occurrence of these events has led some local cli-
nicians to argue for weekly monitoring during the first
month of therapy especially in patients with a Black Brit-
ish background.
Determining causality, in cases of suspected drug induced
hepatitis, can be difficult not least because of concomitant
therapy including possible synergistic effects between
potentially hepatotoxic drugs and alcohol use. One of our
patients was known to consume alcohol to excess and a
majority on other potentially hepatotoxic drugs such as
diclofenac. Diagnostic work-up in our patients also varied
greatly and, understandably, appeared to depend on the
severity of liver disease. In some cases limited diagnostic
testing appeared to reflect greater clinical certainty in the
diagnosis of a drug induced reaction. However the
absence of a comprehensive work up in all cases hampers
retrospective judgments about causality. Various indices
have been developed to assess causality which rely on a
scoring system but there is no agreed gold standard and
agreement between different scales is often poor [13]. We
tested the causality assessment index described by Danan
and Benichou [12] (see Table 2), regarded as essential in
drug induced hepatotoxicity studies [32]. We also used a
simple consensus method similar to the preferred judg-
ments of hepatologists [40]. There was a poor relationship
between our consensus method and the causality assess-
ment index, in part because of dependence on a positive
re-challenge to attain maximum scores with the causality
index. Only one of our patients was re-challenged and
developed an adverse reaction with 48 hours. Clinicians
should beware of re-challenging patients with suspected
hypersensitivity reactions because of reports that even a
small dose on rechallenge can precipitate massive hepatic
necrosis [32,41].
Conclusion
We conclude that serious hepatotoxicity often associated
with a skin rash and variably associated with eosinophilia
occurs within 6 weeks of starting sulfasalazine therapy.
Our experiences indicate that such toxicity is likely to be
missed by current national recommendations for moni-
toring. Toxicity in our series was particularly common in
people of a Black British background of African or Carib-
bean descent. We believe that this adverse drug reaction is
underappreciated and may occur with a frequency as high
as 0.4%. Although this risk frequency is regarded by con-
vention as uncommon the potential severity of reactions
seen may make some patients and practitioners wary of
sulfasalazine.
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